Genetec Corporation has revised its consolidated earnings guidance for the second quarter (interim) and the full fiscal year ending March 2027. The second quarter guidance has been revised downward to net sales of 5,184 million yen, operating income of 47 million yen, ordinary income of 37 million yen, net income attributable to owners of parent (interim) of -22 million yen, and net income per share (interim) of -1.95 yen. Full-year guidance has been revised to net sales of 12,330 million yen, operating income of 700 million yen, ordinary income of 649 million yen, net income attributable to owners of parent of 337 million yen, and net income per share of 29.43 yen. The primary causes are lower utilization in the Engineering Solutions business, increased personnel expenses, and higher depreciation expenses.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4492","jir_company_name":"Genetec Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-09","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4492-20261109-01.pdf","jir_short_summary":"Genetec Corporation has revised its consolidated earnings guidance for the second quarter (interim) and the full fiscal year ending March 2027. The second quarter guidance has been revised downward to net sales of 5,184 million yen, operating income of 47 million yen, ordinary income of 37 million yen, net income attributable to owners of parent (interim) of -22 million yen, and net income per share (interim) of -1.95 yen. Full-year guidance has been revised to net sales of 12,330 million yen, operating income of 700 million yen, ordinary income of 649 million yen, net income attributable to owners of parent of 337 million yen, and net income per share of 29.43 yen. The primary causes are lower utilization in the Engineering Solutions business, increased personnel expenses, and higher depreciation expenses.","jir_summary":"### Summary of Revision to Earnings Guidance\nGenetec Corporation has revised downward its expected results for the second quarter of the fiscal year ending March 2027 and its full-year earnings guidance. Second-quarter net sales are expected to be 5,184 million yen, operating income 47 million yen, ordinary income 37 million yen, net income attributable to owners of parent (interim) -22 million yen, and net income per share (interim) -1.95 yen. For the full year, the company forecasts net sales of 12,330 million yen, operating income of 700 million yen, ordinary income of 649 million yen, net income of 337 million yen attributable to owners of parent, and net income per share of 29.43 yen. The main reasons are delayed recovery of PLM-related projects in the Engineering Solutions business, changes in distribution channels, and cost pressures including increased personnel expenses and higher depreciation.\n\n### Outlook and Measures\nIn the second half, the company expects a positive contribution from the new consolidation of Clas Technology while focusing on overcoming the delayed recovery of PLM-related projects and the impact of the distribution channel change for FlexSim. Although net sales are expected to receive positive contributions from the second half, upside potential for operating income is limited, so the previous forecast for operating income has been maintained. The company will promptly disclose any further revisions depending on future business performance.","jir_financial_highlights":"Net Sales: 5,184 million yen (Compared with previous forecast (5,470) -285 million yen)\nOperating Income: 47 million yen (Compared with previous forecast (80) -32 million yen)\nOrdinary Income: 37 million yen (Compared with previous forecast (65) -28 million yen)\nNet Income Attributable to Owners of Parent (Interim): -22 million yen (Compared with previous forecast (30) -53 million yen)\nNet Income Per Share (Interim): -1.95 yen (Compared with previous forecast (2.62) -4.57 yen)\nNet Sales (Full Year): 12,330 million yen (Compared with previous forecast (11,500) +830 million yen)\nOperating Income (Full Year): 700 million yen (Compared with previous forecast (700) \u00b10 million yen)\nOrdinary Income (Full Year): 649 million yen (Compared with previous forecast (659) -10 million yen)\nNet Income Attributable to Owners of Parent (Full Year): 337 million yen (Compared with previous forecast (365) -28 million yen)\nNet Income Per Share (Full Year): 29.43 yen (Compared with previous forecast (31.58) -2.15 yen)","jir_category":"","jir_hashtags":"#Genetec, #EarningsRevision, #RevisionToEarningsGuidanceNotInterimResults","jir_key_figures":"Net Sales (Second Quarter): 5,184 million yen\nOperating Income (Second Quarter): 47 million yen\nNet Income Attributable to Owners of Parent (Interim, Second Quarter): -22 million yen","jir_meta_title":"Genetec Corporation Revises Earnings Guidance\uff5cFiscal Year Ending March 2027","jir_meta_description":"Genetec Corporation has revised its consolidated earnings guidance for the second quarter and full fiscal year ending March 2027. Second-quarter net sales are 5,184 million yen with interim net income of -22 million yen; full-year net sales are 12,330 million yen with net income of 337 million yen. Key points and causes summarized.","jir_og_title":"Genetec Corporation Revises Earnings Guidance\uff5cFiscal Year Ending March 2027","jir_og_description":"Genetec has revised its earnings guidance for the second quarter and full year ending March 2027. Summary of causes and planned responses.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59859,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"earnings_guidance","footnotes":""},"sector":[],"importance":[],"class_list":["post-144445","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n